Jpmorgan Chase & CO Fulcrum Therapeutics, Inc. Transaction History

Jpmorgan Chase & CO

$1.14 Trillion
Q2 2024

A detailed history of Jpmorgan Chase & CO transactions in Fulcrum Therapeutics, Inc. stock. As of the latest transaction made, Jpmorgan Chase & CO holds 33,041 shares of FULC stock, worth $107,713. This represents 0.0% of its overall portfolio holdings.

Number of Shares

33,041

Previous 158,935 79.21%

Holding current value

$107,713

Previous $1.5 Million 86.4%

% of portfolio

0.0%

Previous 0.0%

13 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 12, 2024	SELL	$5.98 - $9.31 $752,846 - $1.17 Million	-125,894 Reduced 79.21%	33,041 $204,000
Q1 2024 May 10, 2024	BUY	$6.7 - $12.0 $988,216 - $1.77 Million	147,495 Added 1289.29%	158,935 $1.5 Million
Q4 2023 Feb 12, 2024	BUY	$3.18 - $6.86 $1,720 - $3,711	541 Added 4.96%	11,440 $77,000
Q3 2023 Nov 14, 2023	BUY	$3.25 - $6.08 $31,151 - $58,276	9,585 Added 729.45%	10,899 $48,000
Q2 2023 Aug 11, 2023	SELL	$2.26 - $3.8 $427,038 - $718,029	-188,955 Reduced 99.31%	1,314 $4,000
Q1 2023 May 18, 2023	BUY	$2.83 - $13.99 $111,841 - $552,884	39,520 Added 26.22%	190,269 $542,000
Q1 2023 May 11, 2023	SELL	$2.83 - $13.99 $96,041 - $474,778	-33,937 Reduced 18.38%	150,749 $429,000
Q4 2022 Feb 13, 2023	SELL	$5.01 - $8.35 $56,482 - $94,137	-11,274 Reduced 5.75%	184,686 $1.35 Million
Q3 2022 Nov 14, 2022	SELL	$4.92 - $9.1 $10,602 - $19,610	-2,155 Reduced 1.09%	195,960 $1.59 Million
Q2 2022 Aug 11, 2022	SELL	$4.2 - $24.0 $9,538 - $54,504	-2,271 Reduced 1.13%	198,115 $971,000
Q1 2022 May 11, 2022	SELL	$9.96 - $23.65 $24,770 - $58,817	-2,487 Reduced 1.23%	200,386 $4.74 Million
Q4 2021 Feb 10, 2022	BUY	$14.0 - $28.44 $408,044 - $828,912	29,146 Added 16.78%	202,873 $3.59 Million
Q3 2021 Nov 12, 2021	BUY	$7.28 - $30.97 $1.26 Million - $5.38 Million	173,727 New	173,727 $4.9 Million

Others Institutions Holding FULC

# of Institutions

136

Shares Held

59.1M

Call Options Held

4.33M

Put Options Held

309K

View Full List

About Fulcrum Therapeutics, Inc.

Ticker FULC
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 52,038,900
Market Cap $170M
Description
Fulcrum Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing products for improving the lives of patients with genetically defined diseases in the areas of high unmet medical need in the United States. Its product candidates are losmapimod, a small molecule for the treatment of facioscapulohumeral muscular dystro...

More about FULC

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Jpmorgan Chase & CO, based on Form 13F filings with the SEC.

News

Stay updated on Jpmorgan Chase & CO with notifications on news.

Account

Jpmorgan Chase & CO Fulcrum Therapeutics, Inc. Transaction History